Combination Therapy for Alcohol Use Disorder

NCT07249554 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests a combination therapy for reducing participant-reported side effects in adults with alcohol use disorder.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 45 people Planned (estimated).

Who can join Ages 21–65 · all sexes

Timeline Started 2026-07 · est. completion 2028-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07249554 ↗

Description as written by the study sponsor.

This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.

Treatments tested

Placebo Drug

Over-encapsulated non-active microcrystalline cellulose
Glucagon-Like Peptide-1 Agonist (GLP-1) Drug

Over-encapsulated Glucagon-Like Peptide-1 Agonist (GLP-1) oral tablets
Naltrexone (oral tablets) Drug

Over-encapsulated Naltrexone (oral tablets)

Main thing measured	Participant-reported Adverse Events
Sponsor	Johns Hopkins University
Conditions studied	Alcohol Use Disorder
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07249554 ↗